Pembrolizumab-Related Pneumonitis: Signs and Symptoms
Pembrolizumab-related pneumonitis typically presents with new or worsening cough, shortness of breath, increased oxygen requirement, chest pain, and/or fever, though these symptoms are non-specific and require high clinical suspicion. 1
Clinical Presentation
The symptom profile includes:
- Respiratory symptoms: New or worsening cough (often dry), progressive dyspnea, increased oxygen requirement 1, 2, 3
- Constitutional symptoms: Fever, poor appetite, fatigue 2, 4, 3
- Chest discomfort: Chest pain may occur 1
Critical timing consideration: The median time to onset is 3-4 weeks (range: 1.5 to 127 weeks), meaning pneumonitis can occur at any point during or even after treatment cessation. 1 Cases have been documented as early as 48 hours after the first dose 5 and as late as 104 days after the last pembrolizumab cycle. 6
Radiographic Findings
Ground-glass opacities or patchy nodular infiltrates, predominantly in the lower lobes, are the most common CT findings, though presentations vary widely. 1 The FDA label confirms ground-glass opacities as characteristic findings. 7
Specific CT patterns include:
- Organizing pneumonia (OP) pattern - most common (23%) 8
- Hypersensitivity pneumonitis (HP) pattern (16%) 8
- Ground-glass opacities with or without consolidation 8, 2, 4
- Patchy bilateral infiltrates 3, 5
- Unilateral presentations can occur, including rare hydropneumothorax 9
The Fleischner Society identifies five distinct radiologic subtypes: COPD-like, ground-glass opacities, hypersensitivity type, interstitial type, and pneumonitis not otherwise specified. 1
Key Clinical Pitfalls
The most dangerous pitfall is misdiagnosing pembrolizumab pneumonitis as bacterial pneumonia, as both present with similar symptoms (fever, cough, dyspnea) and may coexist. 2, 4 Three critical distinguishing features:
- Persistence despite antibiotics - If respiratory symptoms fail to improve after 1-2 weeks of appropriate antibiotic therapy, strongly consider pembrolizumab pneumonitis 2, 4
- Negative infectious workup - Absence of identified pathogens in sputum, bronchoalveolar lavage, or blood cultures supports immune-related etiology 9, 2, 4
- Procalcitonin levels - Elevated procalcitonin suggests superimposed bacterial infection, which carries worse prognosis 2
Another critical pitfall: Pneumonitis can mimic or coexist with congestive heart failure exacerbation in patients with cardiac comorbidities, requiring careful differentiation. 10
Risk Factors for Higher Incidence
Pembrolizumab pneumonitis occurs in approximately 3.8% of patients overall 8, but certain populations face elevated risk:
- Prior thoracic radiation: 6.0% incidence 8
- History of asthma or COPD: 5.3% incidence 8
- NSCLC or renal cell carcinoma: Higher rates than melanoma 1
- Combination immunotherapy: 10% vs 3% with monotherapy 1
- Smoking history: More common in former/current smokers 8
Severity Spectrum
Pneumonitis severity ranges from mild (grade 1-2) to fatal (grade 5), with 9% mortality reported in one large series. 8 The CT pattern correlates with severity: diffuse alveolar damage (DAD) pattern carries the highest grades and worst prognosis, followed by OP pattern, while NSIP and HP patterns typically present with lower grades. 8
According to FDA labeling, pembrolizumab was discontinued for pneumonitis in 1.6-2.7% of patients across various cancer types, and pneumonitis led to treatment interruption in 2-2.7% of cases. 7
Diagnostic Approach
No symptomatic, pathologic, or radiographic features are pathognomonic for pembrolizumab pneumonitis - diagnosis requires excluding infection, malignancy progression, and other causes. 1
Transbronchial biopsy is generally not required but may help distinguish chronic ICI pneumonitis (organizing pneumonia-like appearance) from lymphangitic tumor spread or infection when the clinical picture is unclear. 1
Recurrence risk: Pneumonitis can recur upon rechallenge (documented in 2 of 7 re-treated patients) 8 or even flare during corticosteroid taper without drug rechallenge. 8, 6